atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day

Rhea-AI Summary

atai Life Sciences (Nasdaq: ATAI) has announced its participation in several investor events in October 2022, including the Roth Inaugural Healthcare Opportunities Conference and Cantor Fitzgerald’s Neurology & Psychiatry Conference. The company aims to transform mental health treatment and will also host a virtual R&D Day on October 25, 2022. During the virtual event, key opinion leaders will discuss innovative approaches to treating mental health disorders. Archived webcasts will be accessible for up to 90 days on atai’s website.

NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October:

• Roth Inaugural Healthcare Opportunities Conference in New York City
  Format: Company presentation
  Date and Time: Thursday, October 6^th, 11:45 a.m. ET – 12:15 p.m. ET
  Conference link: Roth Inaugural Healthcare Opportunities Conference

• Cantor Fitzgerald’s Neurology & Psychiatry Conference in San Francisco
  Format: Industry panels
  Date and Time: Thursday, October 6^th, 2:10 p.m. ET – 3:10 p.m. ET & Friday, October 7^th, 11:00 a.m. – 12:00 p.m. ET
  Conference link: Cantor Fitzgerald’s Neurology & Psychiatry Conference

• atai Life Sciences Virtual R&D Day
  Format: Company presentation and KOL discussions
  Date and Time: Tuesday, October 25^th, 12:00 p.m. ET
  Webcast link: TBA

Archived webcasts will be accessible in the Events section of atai’s website where they will be available for up to 90 days.

About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.

Forward-Looking Statements
These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as updated by our subsequent filings with the SEC, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:
Stephen Bardin
Chief Financial Officer
Email: IR@atai.life

Media Contact:
Allan Malievsky
Senior Director of External Affairs
Email: PR@atai.life

FAQ

What investor events will atai Life Sciences participate in October 2022?

atai Life Sciences will participate in the Roth Inaugural Healthcare Opportunities Conference and Cantor Fitzgerald’s Neurology & Psychiatry Conference.

When is the atai Life Sciences virtual R&D Day?

The atai Life Sciences virtual R&D Day is scheduled for October 25, 2022, at 12:00 p.m. ET.

What is the purpose of atai Life Sciences' presentations in October 2022?

The presentations aim to discuss innovative treatments for mental health disorders and share insights from key opinion leaders.

Where can I access archived presentations from atai Life Sciences?

Archived webcasts of atai Life Sciences’ presentations will be available on their website for up to 90 days.

What is the main focus of atai Life Sciences?

atai Life Sciences focuses on transforming the treatment of mental health disorders through innovative biopharmaceutical development.